2 drugs are better than 1 at targeting tumors with B-RAF mutations
In a proportion of human solid tumors, in particular melanomas (a form of skin cancer that is often resistant to chemotherapy), inappropriate activation of the MEK/ERK signaling pathway as a result of mutations in the B-RAF gene promotes tumor cell growth and survival. Although MEK inhibitors stop such tumor cells growing, they have a limited ability to kill the tumor cells. Thus, they have had limited success in promoting tumor regression in preclinical and clinical trials. A team of researchers, at The Walter and Eliza Hall Institute of Medical Research, Australia, has now uncovered the molecular reasons why MEK inhibitors have only a limited ability to kill B-RAF mutant tumor cells and identified another class of drugs that when combined with MEK inhibitors cause tumor regression in mice transplanted with human B-RAF mutant tumor cells. The team, led by Andreas Strasser and Mark Cragg, found that MEK inhibitors were limited in their ability to kill (by a process known as apoptosis) human B-RAF mutant tumor cells in vitro. The small amount of apoptosis they did induce was mediated via upregulation of the protein Bim. However, if the cells were treated with both a MEK inhibitor and ABT-737 (a drug known as a BH3 mimetic) an extensive amount of apoptosis was observed. Further, the combination also caused tumor regression in mice transplanted with human B-RAF mutant tumor cells; the MEK inhibitor stopped the tumor cells growing and ABT-737 induced the cells to undergo apoptosis. The authors therefore suggest that treating individuals with tumors characterized by B-RAF mutations, especially melanomas, with a MEK inhibitor and a BH3 mimetic might provide a powerful antitumor approach.
Scott Kaufmann and colleagues, at the Mayo Clinic, Rochester, go one step further in their accompanying commentary, asking whether combined MEK inhibitor/BH3 mimetic therapy might be effective for individuals with tumors exhibiting excessive activation of the MEK/ERK signaling pathway in the absence of B-RAF mutations.
- Combining targeted therapy drugs may treat previously resistant tumorsSun, 30 Nov 2008, 14:07:42 EST
- Combining 2 peptide inhibitors might block tumor growthMon, 14 Mar 2011, 17:34:50 EDT
- New cancer treatment targets both tumor cells and blood vesselsWed, 18 Jun 2008, 12:21:21 EDT
- New targeted lung cancer drug produces 'dramatic' symptom improvementWed, 27 Oct 2010, 17:33:20 EDT
- PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humansWed, 17 Nov 2010, 22:37:09 EST
- Two drugs are better than one at targeting tumours with B-RAF mutationsfrom Science CentricFri, 24 Oct 2008, 9:35:46 EDT
- 2 drugs are better than 1 at targeting tumors with B-RAF mutationsfrom PhysorgFri, 24 Oct 2008, 6:07:19 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
No popular news yet
No popular news yet
- Stem cell transplant restores memory, learning in mice
- 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
- Calculating tsunami risk for the US East Coast
- Researchers discover mushrooms can provide as much vitamin D as supplements
- Cutting back on sleep harms blood vessel function and breathing control